Ovarian malignant growth is one of the most well-known gynecologic tumors, and one of the main sources of disease related female mortality on the planet. As of now, no generally acknowledged pathogenesis is accessible, which may clarify the whole ailment. Early recognition and essential anticipation of ovarian disease are troublesome, generally because of its heterogeneous nature. Hazard factor alteration dependent on epidemiologic information has not essentially decreased the frequency of ovarian malignant growth. As of now, prophylactic careful strategies have been proposed as the best preventive measures for both the high-hazard or generally safe populaces. Understanding the current pathogenesis speculations and the careful alternatives accessible may adjust doctor's points of view and encourage better dynamic.
Editor Note: Journal of Cancer Clinical Trials
Editor Note: Journal of Cancer Clinical Trials
Review Article: Journal of Cancer Clinical Trials
Review Article: Journal of Cancer Clinical Trials
Research Article: Journal of Cancer Clinical Trials
Research Article: Journal of Cancer Clinical Trials
Letter to Editor: Journal of Cancer Clinical Trials
Letter to Editor: Journal of Cancer Clinical Trials
Commentary: Journal of Cancer Clinical Trials
Commentary: Journal of Cancer Clinical Trials
Scientific Tracks Abstracts: Journal of AIDS & Clinical Research
Scientific Tracks Abstracts: Journal of AIDS & Clinical Research
Scientific Tracks Abstracts: Journal of Advanced Practices in Nursing
Scientific Tracks Abstracts: Journal of Advanced Practices in Nursing
Posters & Accepted Abstracts: Journal of Cosmetology & Trichology
Posters & Accepted Abstracts: Journal of Cosmetology & Trichology
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report